Skip to main content
SpringerLink
Log in

Multiple Sclerosis

  • Chapter
  • First Online:
Neuropalliative Care

  • 955 Accesses

Abstract

Despite the successes of newer disease modifying therapies for multiple sclerosis, patients and families continue to have enormous palliative care needs. These needs are driven by the long and uncertain trajectory of the heterogeneous physical, psychological, and social effects of this disease. Comprehensive and vigilant multi-disciplinary care is essential to optimize function and quality of life, through treatments and social support systems. Primary palliative care is an essential component to all teams providing care to patients with multiple sclerosis, and they should have ready access to specialist palliative care if needed. Data suggests early palliative care might be useful in MS but more research and education are needed to better define the timing and role of a palliative care approach to patients and families with multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. NEJM. 2000;343:938–52.

    Article  CAS  Google Scholar 

  2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. NEJM. 2006;354:942–55.

    Article  CAS  Google Scholar 

  3. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. NEJM. 2016;376:221–34.

    Article  Google Scholar 

  4. Oliver DJ, Borasio GD, Caraceni A, et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol. 2016;23:30–8.

    Article  CAS  Google Scholar 

  5. Ontanada D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015;28:237–43.

    Article  Google Scholar 

  6. Ontanada D, Thompson A, Fox R, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair and restoration of function. Lancet. 2017;389:1357–66.

    Article  Google Scholar 

  7. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.

    Article  Google Scholar 

  8. Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nat Rev Neurol. 2017;13:105–18.

    Article  Google Scholar 

  9. Giovannoni G, Tomic D, Bright JR, Havrdova E. “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23:1179–87.

    Article  Google Scholar 

  10. Strupp J, Hartwig A, Golla H, et al. Feeling severely affected by multiple sclerosis: what does this mean? Palliat Med. 2012;26:1001–10.

    Article  Google Scholar 

  11. Aridegbe T, Kandler R, Walters SJ, et al. The natural history of motor neuron disease: assessing the impact of specialist care. Amytroph Lat Scler. 2013;14:13–9.

    Google Scholar 

  12. Bede P, O’Brannagain D, Hardiman O. Development of an interactive software for evidence-based symptomatic management of motor neuron disease with specific trigger points to specialist palliative care intervention. Eur J Neurol. 2010;17(S3):291.

    Google Scholar 

  13. Turner-Stokes L, Sykes N, Silber E. Long-term neurological conditions: management at the interface between neurology, rehabilitation and palliative care. Clin Med. 2008;8(2):186–91.

    Article  Google Scholar 

  14. Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017:1–5. https://doi.org/10.1136/jnnp-2016-315238.

    Article  Google Scholar 

  15. Cutter GR, Zimmerman J, Salter AR, et al. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord. 2015;4:484–90.

    Article  Google Scholar 

  16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–11.

    Article  CAS  Google Scholar 

  17. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900–13.

    Article  Google Scholar 

  18. Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: a prospective, non-randomized pilot study. PLoS One. 2017;12:e0173299.

    Article  Google Scholar 

  19. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. Clinical Guideline 186. 2014. NICE www.nice.org.uk/guidance/cg186. (Accessed 27 Jun 2017).

  20. Simmons RD. Life issues in multiple sclerosis. Nat Rev Neurol. 2010;6:603–10.

    Article  Google Scholar 

  21. De Sa JCC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139–68.

    Article  Google Scholar 

  22. Hirsh AT, Turner AP, Ehde DM, Haselkorn JK. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil. 2009;90:646–51.

    Article  Google Scholar 

  23. Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009;16:262–7.

    Article  CAS  Google Scholar 

  24. Chohan H, Greenfield A, Yadav V, Graves J. Use of cannabinoids for spasticity and pain management in MS. Curr Treatm Opt Neurol. 2016;18:1–14.

    Article  Google Scholar 

  25. Kabus C, Hecht M, Japp G, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253(S1):26–8.

    Article  Google Scholar 

  26. Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R. Long-term efficacy of intrathecal baclofen to manage severe spasticity in MS patients. Mult Scler. 2016;22(S3):684–5.

    Google Scholar 

  27. Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285. https://doi.org/10.1155/2014/798285. Epub 2014 May 14.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;7513:1141–9.

    Article  Google Scholar 

  29. Yang TT, Wang L, Deng XY, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017;380:256–61.

    Article  CAS  Google Scholar 

  30. Cameron M. Effects of methylphenidate on mobility, cognition and fatigue in multiple sclerosis: a pilot randomized controlled trial. Neurology. 2017;88(16S):P3.341.

    Google Scholar 

  31. Oliveria SF, Rodriguez RL, Bowers D, et al. Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial. Lancet Neurol. 2017;16:691–700.

    Article  Google Scholar 

  32. Sarkar P, Cole A, Scolding NJ, Rice CM. Percutaneous endoscopic gastrostomy tube insertion in neurodegenerative disease: a retrospective study and literature review. Clin Endosc. 2017;50:270–8.

    Article  Google Scholar 

  33. Pereira CMA, Castiglione M, Kasawara KT. Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis. J Phys Ther Sci. 2017;29:1259–63.

    Article  Google Scholar 

  34. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318:1592–604.

    Article  Google Scholar 

  35. Macleod AD, Formaglio F. Demyelinating disease. In: Voltz R, Bernat JL, Borasio GD, Maddocks I, Oliver D, Portenoy RK, editors. Palliative care in neurology. Oxford: Oxford University Press; 2004. p. 33–4.

    Google Scholar 

  36. Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73:411–7.

    Article  Google Scholar 

  37. Federal Control and Evaluation Committee for Euthanasia. Seventh report to Parliamant. January 1 2014 to December 31 2015. (In Dutch). Available online: http://overlegorganen.gezondheid.belgie.be/sites/default/files/documents/7_euthanasie-verslag_2014-2015-nl_0.pdf. Accessed 25 Jun 2017.

  38. End of life care in long term neurological conditions: a framework for implementation. National End of Life Care Programme 2010. https://www.mssociety.org.uk/ms-resources/endlife-care-long-term-neurological-conditions-%E2%80%93-framework-implementation. Accessed 25 June 2017.

  39. Hussain J, Adams D, Allgar V, Campbell C. Triggers in advanced neurological conditions: prediction and management of the terminal phase. BMJ Supp Palliat Care. 2014;4:30–7.

    Article  Google Scholar 

  40. GSF, G.-S.-F. Proactive Identification Guidance 2016. Available from: http://www.goldstandardsframework.org.uk/library-tools-amp-resources. Accessed 27 Feb 2017.

  41. Topcu G, Buchanan H, Aubeeluck A, Garip G. Caregiving in multiple sclerosis and quality of life: a meta-synthesis of qualitative research. Psychol Health. 2016;31:693–710.

    Article  Google Scholar 

  42. Buchanan RJ, Radin D, Huang C. Caregiver burden among informal caregivers assisting people with multiple sclerosis. Int J MS Care. 2011;13:76–83.

    Article  Google Scholar 

  43. Buchanan RJ, Radin D, Chakravorty BJ, Tyry T. Informal care giving to more disabled people with multiple sclerosis. Disabil Rehabil. 2009;31:1244–56.

    Article  Google Scholar 

  44. Borreani C, Bianchi E, Cilia S, et al. Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One. 2014;9:e109679.

    Article  Google Scholar 

  45. Higginson IJ, McCrone P, Hart SR, et al. Is short-term palliative care cost-effective in Multiple sclerosis? A randomized phase II trial. J Pain Symptom Manag. 2009;38:816–26.

    Article  Google Scholar 

  46. Edmonds P, Hart S, Gao W, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16:627–36.

    Article  Google Scholar 

  47. Solari A, Giordano G, Patti F, et al. Randomised controlled trial of a home based palliative approach for people with severe muliple sclerosis. Mult Scler. 2017. https://doi.org/10.1177/1352458517704078epubaheadofprint.

  48. OPTCARE NEURO – https://www.kcl.ac.uk/nursing/departments/cicelysaunders/research/studies/OPTCARE-Neuro/index.aspx. Accessed 250 Jun 2017.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, AZ Sint Jan Brugge Oostende, Brugge, Belgium

    Ludo J. Vanopdenbosch MD, FAAN

  2. Tizard Centre, University of Kent, Canterbury, Kent, UK

    David J. Oliver BSc, MBBS, FRCP, FRCGP

Authors
  1. Ludo J. Vanopdenbosch MD, FAAN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Oliver BSc, MBBS, FRCP, FRCGP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ludo J. Vanopdenbosch MD, FAAN .

Editor information

Editors and Affiliations

  1. Assistant Professor, Department of Neurology, University of Washington Harborview Medical Center, Seattle, WA, USA

    Claire J. Creutzfeldt

  2. Professor of Neurology, Chief Neurology Supportive and Palliative Care Section, Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    Benzi M. Kluger

  3. Professor and Edward A. and Alma Vollertsen Rykenboer Chair, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

    Robert G. Holloway

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vanopdenbosch, L.J., Oliver, D.J. (2019). Multiple Sclerosis. In: Creutzfeldt, C., Kluger, B., Holloway, R. (eds) Neuropalliative Care. Springer, Cham. https://doi.org/10.1007/978-3-319-93215-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93215-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93214-9

  • Online ISBN: 978-3-319-93215-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation